MLMarie-Laure Laroche

Marie-Laure Laroche

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marie-Laure Laroche has a total of 410 co-authors. Here are the top co-authors by number of shared publications:

  • Louis Merle

    Service de pharmacologie, toxicologie et pharmacovigilance, UMR 1248, CHU de Limoges, université de Limoges, Inserm, 87042 Limoges, France

    19 shared publications
  • Caroline Sirois

    Faculty of Pharmacy, Université Laval, Quebec City, Canada

    11 shared publications
  • Lucas Morin

    Inserm CIC 1431, University Hospital of Besançon, Besancon, France

    7 shared publications
  • Barbara Roux

    Centre of Pharmacovigilance and Pharmacoepidemiology, Department of Pharmacology Toxicology and Centre of Pharmacovigilance, University Hospital of Limoges, Limoges, France

    6 shared publications
  • Hélène Géniaux

    Centre of pharmacovigilance, Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, 87042 Limoges, France

    6 shared publications
  • Kristina Johnell

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

    6 shared publications

Latest Publications

  • Open Access

    Clinical phenotypes and age-related differences in SGLT2 inhibitor-associated ketoacidosis: A nationwide pharmacovigilance case-series study

    by Nathanaël Bassas Letissier, Nassir Mirfendereski, Marie-Laure Laroche, Jean-Luc Faillie, Marc Paccalin, Marlène Damin-Pernik, Sophie Fedrizzi, Brahim Azzouz, Bérenger Largeau, Pierre-Jean Saulnier, et al.

  • Open Access

    Quality and reliability of antidepressant-related content on Instagram and TikTok

    by Ophélie Marqué, Jérémy Couturas, Clément Mathieu, Marie-Laure Laroche, Laurence Schadler

  • Open Access

    Deprescription of Psychotropics in Children and Adolescents: Systematic Review of Guidelines and Development of a Deprescribing Algorithm

    by Paul‐Benoît Fargier, Mark Horowitz, Rodolphe Charles, Valérie Rousselon, Erik Fakra, Marie‐Noëlle Beyens, Marie‐Laure Laroche

    Background: Psychotropics are increasingly prescribed in paediatrics despite limited evidence regarding their benefits and effectiveness. Although deprescribing approaches are established in adults, structured paediatric strategies remain poorly defined. Aims: To identify and evaluate clinical practice guidelines (CPGs) on psychotropic deprescribing in youth, to describe and discuss recommendations regarding when and how to deprescribe in practice. Methods: We systematically searched PubMed, Embase, PsycInfo, Scopus, Web of Science and grey literature (2015–2025). Two reviewers independently screened and evaluated the quality of the guidelines (AGREE II). We derived from this a psychotropic deprescribing algorithm in youth, supplemented with clinical expertise. Results: Among the 1390 records identified, none strictly met the methodological criteria for formal CPGs. Nevertheless, we assessed two papers that provided practical deprescribing recommendations and shared several characteristics with CPGs. One systematic review focused on antidepressant discontinuation, recommending tapering after remission with gradual dose reduction and monitoring to distinguish withdrawal from relapse. One narrative review provided child‐specific guidance for stimulants, recommending reassessment and possible discontinuation after 1 year of stability. Both were rated as ‘moderate’ using the AGREE II tool and provided limited practical detail on stepwise deprescribing procedures. Conclusion: Critical gap and urgent need for paediatric‐specific deprescribing guidelines. We propose an expert‐informed stepwise deprescribing algorithm.


  • Open Access

    Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review

    by Marie-Laure Laroche, Hélène Géniaux, Manon Jardou

    Purpose: An increasing number of anecdotal reports on social media platforms and medical blogs describe dysesthesia, particularly burning skin sensations, in association with glucagon-like peptide-1 receptor (GLP-1R) agonists. We performed a pharmacovigilance data-mining analysis to characterise cases of dysesthesia related to GLP-1R. Methods: We conducted a disproportionality analysis using VigiBase data on GLP-1R (Anatomical Therapeutic Chemical classification: ATC code A10BJ) and tirzepatide, focusing on the HLT (High Level Term) “Paraesthesia and dysesthesia”, with the Information Component (IC). Additionally, we reviewed all narratives of dysesthesia cases in the French Pharmacovigilance database to extract clinical and pharmacological characteristics. A literature review complemented this analysis. Results: Exenatide was significantly associated with hypoesthesia or oral paraesthesia, semaglutide and tirzepatide with hyperaesthesia, and semaglutide with dysesthesia and burning sensation. Dysesthesia appears to be dose-dependent, occurring more frequently at higher doses and with more potent GLP-1R, whether used for weight management or type 2 diabetes. Discontinuation was often performed, followed by spontaneous favourable outcomes, and cases of rechallenge were observed. Skin burning sensations represent a distinctive form of dysesthesia. Conclusion: Pharmacovigilance quantitative and qualitative data strengthens evidence for dysesthesias associated with GLP-1R agonists already observed in clinical trials of semaglutide, tirzepatide, and retatrutide.


  • Open Access

    Medication errors in a residential care facility for adults with intellectual disabilities and in a psychiatric hospital

    by Robin Lebas, Laurence Schadler, Claire Villeneuve, David Fontanier, Marie-Laure Laroche

  • Open Access

    Recognizing Arthralgia as a Potential Adverse Effect of CFTR Modulators: A Case Report

    by Flora Charbonneau, Magali Dupuy-Grasset, Jeanne Languepin, Marie-Laure Laroche

  • Open Access

    Information about Antidepressants for Young People on Instagram and TikTok : Cross-sectional Analysis of Content Quality and Reliability (Preprint)

    by Ophélie Marqué, Jeremy Couturas, Clément Mathieu, Marie-Laure Laroche, Laurence Schadler

    BACKGROUND Access to accurate and appropriate information is essential to support treatment adherence and compliance. In a context marked by both the increasing use of antidepressants among young people and the rise of social media, adolescents and young adults are increasingly turning to Instagram and TikTok for health information, exposing themselves to the risk of misinformation. This trend highlights the importance of evaluating the quality of drug-related content shared on these platforms. OBJECTIVE To assess the quality and reliability of information about antidepressants for young people on the social media platforms Instagram and TikTok. METHODS A cross-sectional analysis of 200 French-language publications (100 from each platform) was conducted using the DISCERN scale, along with additional measures for accuracy, promotion of adherence and audience. The evaluations were performed by three independent evaluators. Descriptive and univariate analysis were carried out to compare the characteristics of information between the two media platforms according to the ‘s qualification. RESULTS The overall quality was considered as "mediocre" (DISCERN score = 32.0±10.5) with health professionals providing significantly of higher quality, more reliable, more accurate, and more likely to promote adherence than non-health professionals (p<0.001). The misinformation rate was of 23.6% and 30.7% of publications discouraged drug adherence. The main topics addressed were the effectiveness of antidepressants (27.3%) and their adverse effects (23.9%), with the most common being weight gain, withdrawal syndrome, and sexual dysfunction. CONCLUSIONS This study reveals an unsatisfactory quality of information about antidepressants aimed at young people via media social, with a worrying proportion of misinformation. These results highlight the need for initiatives to promote the dissemination of accurate and reliable information in order to improve the effectiveness of antidepressants and prevent their risks. CLINICALTRIAL no applicable

  • Open Access

    Cannabinoids and Adverse Convulsive Effects: A Pharmacovigilance and Addictovigilance Analysis of Cases Reported in France

    by Marie‐Laure Laroche, Marion Labetoulle, Emilie Jouanjus, Edeltraut Kröger, Arsène Zongo

    Background: Seizures after the use of cannabinoids are reported, but no precise descriptions of the characteristics of subjects and factors that may trigger seizures are available. Objectives: To study the characteristics and circumstances associated with the occurrence of seizures in individuals using cannabinoids for medical or recreational purposes. Methods: A retrospective analysis of spontaneous reports of adverse drug effects issued by the French pharmacovigilance and addictovigilance systems, and by manufacturers, extracted data from the Eudravigilance database (01/01/1985–21/07/2023). The request used the broad MedDRA SMQ term ‘convulsive’, with all products containing cannabinoids (THC, CBD, cannabis or natural cannabinoids). Results: Among 4296 notifications with cannabinoids, 130 (3%) reports of convulsive effects were analysed: 29 cases (23.3%) related to medical use (27 CBD, 1 THC and 2 combined THC/CBD preparations) and 98 (75.4%) related to recreational use. The median age was 29.0 years (min‐max: 3–75), 78.7% were men and 81.1% were serious cases. Among the recreational users, 38.8% used Cannabis sativa with a history of epilepsy, and 68.4% of them were taking antiepileptics. In total, 67.7% of individuals had at least one risk factor for seizures, i.e., 31.0% among medical users and 78.6% among recreational users. The main risk factors with medical use were inefficacy of CBD (17.2%), fatigue (13.8%) and concomitant epileptogenic medications (10.3%). The main risk with recreational use was concomitant epileptogenic medications (39.8%), consumption of illicit drugs (33.7%) and alcohol (32.7%). Conclusion: This analysis demonstrates the importance of alerting cannabinoid users, particularly recreational cannabis users and those with a history of epilepsy, about seizure‐associated risks. Moreover, educational information should be provided together with the prescription of licensed cannabinoids and medical cannabis.